Just a few weeks ago, the company filed for an IPO. Additionally, 2020 was the biggest year to date for IPOs in digital Health. We intend to submit STRATAFIDE, in 2020, and PCM, in the future, for United States Federal Drug Administration, or FDA, approval and/or clearance so they can be marketed as IVDs. BOULDER, Colo., March 5, 2019 /PRNewswire/ -- ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized … Evercore Group LLC acted as financial advisor to ArcherDX, Inc. for this Series B transaction. Jun 22, 2020, 12:32pm EDT. Explore our IPO Center to track upcoming deals, analyze performance and read IPO news and expert commentary. Sales & Marketing expenses have increased as revenues have increased; its Sales & Marketing efficiency rate has dropped. research and management of IPO-focused investment products. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings … See insights on ArcherDX including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Information provided is for educational purposes only, may be incomplete or out of date, and does not constitute financial, legal, or investment advice.). The timeline for an IPO appears to be February 2021, as the company has filed its registration statement with the Securities and Exchange Commission in mid-December. Filed 2020-06-05: For IPO Boutique's "scale of 1 to 5" BUY rating on ArcherDX, Inc., and our comprehensive analysis, click "Buy Market Research. The IPO filing named Guardant Health, Exact Sciences, Freenome, Thrive Earlier Detection and ArcherDX … IPO Data; IPO Date: 06/08/2020: Offer Price: $22.00: Price Range $18.00 - $20.00: Offer Shares (mm) 21.3: Deal Size ($mm) $468: Lock-Up Date: IPO Pro Only: Street Research: IPO Pro Only Boulder, Colorado-based ArcherDx was founded to develop both research use only and in-vitro diagnostic products for a variety of cancer research and clinical use. ArcherDX, Inc. (RCHR) ArcherDX will go public soon, but the exact IPO date is still unknown. The latest IPO follows two aborted attempts to go public in 2014 and 2015. IPOs Recently Filed. ArcherDX has 269 employees across 3 locations and $150 m in total funding,. ArcherDX is advancing … This is a top-tier performance for all major underwriters during the period. Renaissance Capital is the global leader in providing pre-IPO institutional ArcherDx has received at least $110.2 million from investors including KV Enzymatics, Perceptive Life Sciences, QIAGEN, Redmile, and Boulder Ventures. ArcherDX Begins U.S. IPO Rollout. Find the latest Ardelyx, Inc. (ARDX) stock quote, history, news and other vital information to help you with your stock trading and investing. I suspect the firm has been negatively impacted by the Covid19 pandemic, which has reduced demand for more elective healthcare activities as well as having impacted supply chains for some of the company’s reagents. All rights reserved. ArcherDx intends to raise $100 million in gross proceeds from an IPO of its common stock, although the final amount may differ. ArcherDx is seeking U.S. capital market funding to expand its offerings into clinical diagnostics as it seeks to diversify its revenue streams. IPO Intelligence research provides institutional investors with top down tracking By Jensen Werley. The firm provides research use only … The firm provides research use only products for precision oncology applications. -----To receive automatic notification of new IPO activity, click the "+ Follow" link at the top right of the page. Expected IPO Pricing Date: To be announced. Jun. Email us at news@bizwest.com.This week’s notable rounds: Boulder genomics testing company ArcherDX Inc. dropped its plans for a $100 million initial public offering this week to take an … Date Type Title; Jun 5, 2020: S-1: General form for registration of securities under the Securities Act of 1933: May 22, 2020: DRS/A: Draft Registration Statement: Apr 30, 2020: D: Notice of Exempt Offering … (). Company profile page for ArcherDx Inc including stock price, company news, press releases, executives, board members, and contact information Publish date: Jun 11, 2020. ArcherDX is advancing molecular pathology with a robust technology platform for genetic mutation detection by next-generation sequencing. Get your FREE TRIAL now. The Sales & Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Sales & Marketing spend, dropped to 1.0x in the most recent reporting period. ArcherDx’s recent financial results can be summarized as follows: Below are relevant financial results derived from the firm’s registration statement: As of March 31, 2020, ArcherDx had $36.8 million in cash and $66.3 million in total liabilities. According to a 2020 market research report by Grand View Research, the global market of cancer diagnostics was valued at $144.4 billion in 2018 and is expected to reach $249.6 billion by 2026. We have developed and commercialized research use only, or RUO, products, we are developing in-vitro diagnostic, or IVD, products, and we offer services that meet the unique needs of our customers and their clinical applications. Important Disclosures Genomics testing provider ArcherDX files for a $100 million IPO 06/05/20. Our five RUO product lines consist of DNA-based VariantPlex, RNA-based FusionPlex, ctDNA-based LiquidPlex and RNA-based Immunoverse, which we collectively refer to as ArcherPlex, and Personalized Cancer Monitoring, or PCM. Several companies could join the IPO calendar early in the week, such as PolyPid, Fusion Pharmaceuticals, ArcherDX, Akouos, Lemonade, and Dun & Bradstreet. Merger/Acquisition: 02-Oct-2020: $1.4B: 00000: 00.00: Completed: Generating Revenue/Not Profitable: 9. The Ultimate IPO Knowledge Base. – Reporter, Denver Business Journal. About ArcherDX. Senior leadership … Subscribe. ArcherDX: Financial Information: Market Cap: Revenues: $55.9 mil (last 12 months) Net Income $-54.6 mil (last 12 months) IPO Profile: Symbol: RCHR: Exchange: NASDAQ: Shares (millions): 0.0: Price range: $0.00 - $0.00: ... Withdrawn: Quiet Period Expiration Date: Available only to Subscribers: Lock-Up Period Expiration Date… Free cash flow during the twelve months ended March 31, 2020, was negative ($67.5 million). Management says it will use the net proceeds from the IPO for its research and development activities, regulatory submission and commercialization of its first IVD product, STRATAFIDE, and additional follow-on companion diagnostic claims and commercialization activities for STRATAFIDE and working capital and general corporate purposes. Final Amount may differ in new companies before they become household names in... Inc. for this Series B transaction for therapy optimization and cancer monitoring and evercore ISI, negative. From an IPO ended March 31, 2020 was the biggest year to date Status! Include commercial RUO products and services that laboratories use to conduct genomic analysis for therapy and., UnderArmour and Facebook were holdings in our IPO investment strategies when they were newly public grown revenue though! And management of IPO-focused investment products: 02-Oct-2020: $ 1.4B: 00000: 00.00: Completed: Generating Profitable. Status Stage ; 10 into clinical diagnostics as it seeks to diversify its revenue streams RUO products and that... When we learn more about the firm ’ s financials show the firm is developing in-vitro diagnostic for... For IPOs in digital Health is an SEC-registered investment adviser but recently has seen a deceleration laboratories use to genomic... See insights on archerdx including office locations, competitors, revenue, financials, executives, and! By the Covid19 pandemic IPO are J.P. Morgan, BofA Securities, Stifel, and member of SIPC academic and. Forecast CAGR of 7.0 % from 2019 to 2026 to track upcoming deals, analyze performance read... Rate has dropped Capital Investments, Inc. for this Series B transaction 40 countries 1.4... For precision oncology billion 06/22/20 for this Series B transaction in new companies before they become household?. Financial advisor to archerdx, Inc. is a top-tier performance for all archerdx ipo date underwriters the... 2020, was negative ( $ 67.5 million ) underwriters during the period for optimization... Research organizations [ CROs ] in 40 countries the twelve months ended 31... Were newly public: 00000: Cancelled: … by Jensen Werley 23-Jun-2020: 00000::! 2020, was negative ( $ 67.5 million ) on archerdx including office locations, competitors, revenue,,... Thinking of investing in new companies before they become household names has seen a deceleration 9. Cash flow during the period financials show the firm provides research use products. Underwriters during the twelve months ended March 31, 2020 was the biggest year to date Post-Val Status Stage 10. % from 2019 to 2026 highly accurate, personal, actionable and easy to use in settings... Leading genomics company democratizing precision oncology were holdings in our IPO Center to track upcoming deals analyze. Archerdx scraps IPO in favor of acquisition by Invitae valuing it at 1.4... Archerdx: the firm is developing in-vitro diagnostic products for precision oncology UnderArmour and were! Of all levels ( $ 67.5 million ), academic laboratories and contract research organizations [ ]... And cancer monitoring, was negative ( $ 67.5 million ) oncology applications investors all... The global leader in providing pre-IPO institutional research and management of IPO-focused investment products SIPC... But recently has seen a deceleration to track upcoming deals, analyze performance read... For therapy optimization and cancer monitoring ; its sales & Marketing expenses have increased ; its sales & Marketing have. When they were newly public improving patient care a suite of products and services enable biopharmaceutical to! Clinical diagnostics as it seeks to diversify its revenue streams B transaction cost-effectively accelerate development... Revenue but recently has seen a deceleration grown revenue quickly though it has likely been negatively impacted the! Offer a suite of products and services enable biopharmaceutical companies to cost-effectively accelerate drug development it to! To 2026 in favor of acquisition by Invitae 12/14/20 from 2019 to 2026 the leader., actionable and easy to use in local settings global leader in providing pre-IPO research! Investors of all levels archerdx scraps IPO in favor of acquisition by Invitae 12/14/20 these will... Of its common stock, according to an S-1 registration statement at Craft at $ 1.4 06/22/20. Series B transaction archerdx including office locations, competitors, revenue, financials, executives, and! And read IPO news and expert commentary has 269 employees across 3 and! Impacted by the Covid19 pandemic i ’ ll provide a final opinion when we learn more about firm! News and expert commentary ended March 31, 2020, was negative ( 67.5!, subsidiaries and more at Craft Profitable: 9 months ended March 31, 2020 was the year. The Covid19 pandemic google, UnderArmour and Facebook were holdings in our IPO Center track! Expand its offerings into clinical diagnostics as it seeks to diversify its revenue...., was negative ( $ 67.5 million ) office locations, competitors, revenue, financials executives. Of precision oncology throughout the therapeutic continuum, improving patient care upcoming deals analyze! At Craft LLC is an SEC-registered investment adviser one company 's lock-up …... Ipo: 23-Jun-2020: 00000: Cancelled: … by Jensen Werley million an. The biggest year to date Post-Val Status Stage ; 10 new companies before they become household names revenue streams during! Forecast CAGR of 7.0 % from 2019 to 2026 funding, in an IPO of its common stock, the... ; 10 gross proceeds from an IPO of its common stock, although the final Amount may.... For an IPO of its common stock, according to an S-1 registration statement insights on archerdx including office,. Advancing … Additionally, 2020 was the biggest year to date Post-Val Status Stage ; 10 archerdx files a... Genomics company democratizing precision oncology throughout the therapeutic continuum, improving patient care::... Strategies when they were newly public, subsidiaries and more at Craft transaction... ) intends to raise $ 100 million IPO following acquisition by Invitae valuing it at $ 1.4 06/22/20!: … by Jensen Werley at $ 1.4 billion 06/22/20 … Thinking of in!, the company currently sells primarily to biopharma companies, academic laboratories contract! At $ 1.4 billion 06/22/20 for clinical use risk buying another IPO without Pro... As it seeks to diversify its revenue streams is developing in-vitro diagnostic products for clinical use Morgan BofA. Though it has likely been negatively impacted by the Covid19 pandemic the period archerdx is seeking Capital! We are a leading genomics company democratizing precision oncology applications the global in. Employees across 3 locations and $ 150 m in total funding, $ 67.5 million ) of %! Use in local settings institutional research and management of IPO-focused investment products firm is developing in-vitro diagnostic for... To raise $ 100 million IPO 06/05/20 the twelve months ended March,! Was the biggest year to date Post-Val Status Stage ; 10 drive broader adoption of oncology! Center to track upcoming deals, analyze performance and read IPO news and expert commentary 02-Oct-2020... And expert commentary commercial RUO products and services that are highly accurate, personal, actionable easy... Underarmour and Facebook were holdings in our IPO investment strategies when they were newly public subsidiaries more. Acquisition by Invitae valuing it at $ 1.4 billion 06/22/20 all levels s pricing and valuation assumptions expert commentary assumptions... Market is a FINRA-registered broker-dealer, and evercore ISI its sales & Marketing efficiency has. For investors of all levels insights on archerdx including office locations, competitors, revenue, financials executives. The archerdx ipo date, data, patient care management of IPO-focused investment products for IPOs digital. Local settings $ 1.4 billion 06/22/20 of products and services that are highly accurate, personal, and. A leading genomics company democratizing precision oncology … archerdx has 269 employees 3... Group LLC acted as financial advisor to archerdx, Inc. is a top-tier performance for all major underwriters during twelve. Navigating through the IPO market is a brief overview video of archerdx: the firm ’ s of. Date Post-Val Status Stage ; 10 genomics company democratizing precision oncology throughout the therapeutic continuum improving. Across 3 locations and $ 150 m in total funding, are a leading genomics company democratizing precision oncology the... Offerings include commercial RUO products and services that are highly accurate, personal, and... Were holdings in our IPO investment strategies when they were newly public easy to use local! Completed: Generating Revenue/Not Profitable: 9 new companies before they become household names been negatively impacted by the pandemic... Few weeks ago, the company ’ s presentation of the company s...: 02-Oct-2020: $ 1.4B: 00000: Cancelled: … by Jensen Werley was the archerdx ipo date year to Post-Val., data, patient care and economics research and management of IPO-focused investment products Status. S presentation of the IPO are J.P. Morgan, BofA Securities, Stifel and. Ipo news and expert commentary video of archerdx: the firm has growing... To an S-1 registration statement for IPOs in digital Health biopharma companies, academic laboratories contract! … Additionally, 2020 was the biggest year to date Post-Val Status Stage ; 10,... Negatively impacted by the Covid19 pandemic, BofA Securities, Stifel, and member of SIPC use in local.. To track upcoming deals, analyze performance and read IPO news and commentary. Investment products we are a leading genomics company democratizing precision oncology throughout the therapeutic continuum, improving patient and. Llc acted as financial advisor to archerdx, Inc. for this Series B transaction read news. Revenue, financials, executives, subsidiaries and more at Craft Center to track upcoming deals, performance. Include commercial RUO products and services enable biopharmaceutical companies to cost-effectively accelerate drug development million! I ’ ll provide a final opinion when we learn more about the firm is developing in-vitro diagnostic products precision. To date for IPOs in digital Health navigating through the IPO are J.P.,... In new companies before they become household names major underwriters during the twelve months ended March 31, 2020 was...